Brief: Heidelberg Pharma To Start Phase I/IIa Clinical Trial With ATAC Candidate HDP-101
19/07/2021 15:19
July 19 (Reuters) - HEIDELBERG PHARMA AG HPHA.DE :
* PAUL EHRLICH INSTITUTE ALLOWS HEIDELBERG PHARMA TO START A
PHASE
I/IIA CLINICAL TRIAL WITH ATAC CANDIDATE HDP-101
* INITIATION OF FIRST GERMAN STUDY CENTER PLANNED WITHIN
NEXT FEW
MONTHS
Source text for Eikon: ID:nEQ10mHHja
Further company coverage: HPHA.DE
(Gdansk Newsroom)
((Gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Heidelberg Pharma AG
See all newsBrief: Heidelberg Pharma And Huadong Medicine Receive Nmpa Approval For Hdp-101 Trial In China
Germany's Heidelberg Pharma H1 sales revenue surges, driven by milestone payments
Brief: Heidelberg Pharma Says Co. And Healthcare Royalty Announce Amendment To Existing Royalty Agreement
Brief: Redhill Biopharma Secures Allowance Of Key Chinese Patent Application For Proprietary COVID-19 Treatment, RHB-107
Brief: Heidelberg Pharma Amends Royalty Financing With Healthcare Royalty